Average difference in mean daily active calories in the week before and after the specified software transition, using different minimum data thresholds. by Shelby L. Sturrock (10751675)

Subjects:

Comparison of questionnaire scores among genotypes for the significant associations. by Dai Nogimura (21445649)

Comparison of HRV and STAI between intervention and control at Pre-CRI:SIS and Post-CRI-SIS shifts from linear mixed model for repeated measures. by Leigh V. Evans (19753987)

A slight negative trend in the relationship between U-Cd levels and BMD in both 2019 and 2022, as evident from the slightly downward-sloping regression lines in both years. However... by Aroon La-up (14095691)

Subjects:

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Mean AIV-H9N2 shedding titer (Log₁₀) in oropharyngeal swabs. by Oumayma Arbani (21001472)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Distance-based redundancy analysis (dbRDA) plot performed from the distance-based linear model permutation test (DistLM) that describes the aggregation of sampling stations at ever... by Francisco Flores-de-Santiago (20391063)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects: